Retatrutide Pharmacokinetics: Half-Life, Steady State, and Dosing

Before you can understand how retatrutide is dosed, why the titration schedule looks the way it does, or what happens when you miss a weekly injection, you need to know its pharmacokinetic profile. Retatrutide's half-life of approximately 6 days makes it structurally similar to semaglutide and tirzepatide in terms of dosing interval — but there are meaningful differences in how the drug accumulates and how quickly steady state is achieved.

This covers the PK data from the published Phase 2 trial and what it tells you about the drug's real-world behavior.

What Pharmacokinetics Actually Measures

Pharmacokinetics (PK) describes what the body does to a drug: how it's absorbed after injection, how it distributes through the body, how it's metabolized, and how it's eliminated. The key parameters for a once-weekly GLP-1 agonist are:

• Half-life (t½): How long it takes for the plasma concentration to fall by 50%. This determines dosing interval.
• Time to steady state: How many weeks of dosing it takes before peak and trough concentrations stabilize at a plateau. Typically 4–5 half-lives.
• Accumulation ratio: How much higher the steady-state concentration is compared to after the first dose. Higher accumulation ratio = larger gap between "how you feel week one" and "how you feel at maintenance."
• Bioavailability: For a subcutaneous injection, how much of the dose actually enters systemic circulation.

For most GLP-1 receptor agonists, the dominating PK consideration is the half-life — it's what determines once-weekly vs. once-daily dosing, and it shapes the titration schedule.

Retatrutide's Half-Life: ~6 Days

The Phase 2 dose-ranging trial published by Jastreboff et al. in the New England Journal of Medicine (2023) included PK characterization across the five dose arms studied. The data placed retatrutide's terminal half-life at approximately 6 days following subcutaneous injection.

This positions retatrutide in the same general territory as semaglutide (~7 days) and tirzepatide (~5 days):

A 6-day half-life is why retatrutide is dosed once weekly rather than once daily. There's enough drug circulating to maintain receptor engagement throughout the week without daily injections. The slightly shorter half-life relative to semaglutide means trough concentrations (just before the next dose) are modestly lower, but the clinical significance of this difference in the weekly dosing window is likely small.

Steady State: ~4 Weeks After Starting Each New Dose

Steady state is the point at which the amount of drug entering the body with each dose equals the amount being eliminated between doses. Drug continues to accumulate in the body until that balance is reached.

For retatrutide, with a ~6 day half-life, it takes approximately four half-lives to reach ~94% of steady state — roughly four weeks of consistent weekly dosing at a given dose. Full steady state (technically defined as 97–99%) takes five half-lives, or about five weeks.

In practical terms, this means:

• Week 1 after starting (or after a dose increase): You're at a fraction of eventual steady-state exposure. The drug's effects are present but submaximal.
• Weeks 2–3: Concentrations rise toward steady state. Side effects often worsen during this window as exposure increases.
• Week 4+: Concentrations stabilize. This is where you get your clearest picture of how your body responds to that dose level.

This pattern is why retatrutide's titration schedule keeps patients at each dose for at least 4 weeks before stepping up. Moving faster doesn't let you assess whether the current dose is tolerated or effective — you'd be stepping up during the accumulation phase, not after it.

The accumulation ratio for retatrutide is reported at approximately 3-fold in the Phase 2 data — meaning steady-state exposure is roughly three times the exposure after the first dose at that level. This is similar to semaglutide and tirzepatide, where first-dose tolerability often looks deceptively manageable compared to weeks 3–4 of the same dose.

The Titration Schedule and PK

Retatrutide has been studied in dose arms ranging from 1 mg to 12 mg weekly in Phase 2. The Phase 3 titration schedule used in the TRIUMPH program starts at a low dose and escalates every 4 weeks as tolerated, targeting the 8 mg or 12 mg maintenance doses depending on response.

The PK rationale for 4-week steps:

1. Each new dose needs 4 weeks to reach steady state — any faster and you're escalating before the previous dose has settled
2. GI side effects are worst during accumulation — most nausea, vomiting, and reflux emerges in weeks 2–3 of a new dose level, then attenuates as the gut adapts. Staying at a dose for 4 weeks usually captures the worst of it; moving at 2 weeks might mean leaving before the gut has adapted
3. Efficacy signal at each dose requires steady state — if you're evaluating whether 8 mg is working better than 4 mg, you can't assess that comparison until each dose has been at steady state

This is the same logic behind the Wegovy and Mounjaro titration schedules, but it's especially relevant for retatrutide because the dose range is wider and the top dose is higher than either predecessor drug.

What Happens If You Miss a Dose

With a ~6 day half-life and weekly dosing, missing a single injection means you're injecting at roughly 2 half-lives from the last dose. At that point, plasma concentration has dropped to approximately 25% of its post-injection peak. The drug is still present and active, but the drop is meaningful.

Practical guidance (consistent with the Phase 3 protocol):

• Missed dose, less than 4 days late: Take it as soon as you remember, then return to your regular weekly schedule
• Missed dose, more than 4 days late: Skip the missed dose and take your next one on the scheduled day — don't double up
• Missed multiple doses: Resume at the most recently tolerated dose level; you may need to re-titrate depending on how long you've been off

The key point is that plasma concentration doesn't cliff-drop overnight with a weekly drug. A day-late injection is not a crisis. Three weeks off, however, means you're essentially starting from a very low exposure level and the same GI side-effect accumulation can recur on re-introduction.

How Retatrutide PK Compares to Tirzepatide

The most clinically relevant comparison is tirzepatide, since both are Eli Lilly molecules with similar dosing intervals and similar overall efficacy profiles.

Similarities:

• Both are once-weekly subcutaneous injections
• Both reach steady state in approximately 4–5 weeks
• Both require the same style of stepped titration schedule
• Both are cleared primarily via proteolytic degradation (the same pathway that degrades endogenous peptides)

Differences:

• Retatrutide's half-life (~6 days) is modestly longer than tirzepatide's (~5 days), meaning troughs are slightly higher relative to peak for retatrutide — concentrations are marginally more stable across the week
• Retatrutide's higher maintenance doses (up to 12 mg vs tirzepatide's 15 mg, but on a per-molecule basis the comparison is complex because the two drugs have different binding affinities)
• The glucagon receptor component of retatrutide means its mechanism of action diverges from tirzepatide in meaningful ways, even if the PK profiles look broadly similar

The retatrutide vs tirzepatide post goes deeper on efficacy. For the PK picture specifically: both drugs behave similarly from a dosing management standpoint. What you learn about managing tirzepatide injections and missed doses transfers directly to retatrutide.

PK Is Phase 2 Data — Phase 3 Hasn't Changed the Picture, But Is Larger

The half-life and steady-state values cited here come primarily from the Phase 2 trial (338 participants). Phase 3 data from the TRIUMPH program is from a larger, more diverse population, but the PK profile of a molecule doesn't change based on trial size — it's a property of the drug's structure. Phase 3 confirms the Phase 2 PK signal holds up across a broader sample.

Where Phase 3 matters more than Phase 2 for this topic is in understanding how individual patient variation (body weight, renal function, injection technique) affects PK parameters across a more representative population. Those analyses will emerge in the full Phase 3 publications.

What This Means in Practice

For a patient starting retatrutide, the PK profile translates to a few concrete expectations:

• Weeks 1–3 at any new dose are not representative of how you'll feel at steady state — judge tolerability and efficacy at weeks 4–6 of a stable dose
• Missing one weekly dose is not a catastrophic event, but missing several in a row may require re-titrating from a lower dose
• The titration schedule is calibrated to the half-life — pushing faster than the protocol typically increases side effects without improving efficacy

For more on how the TRIUMPH trials demonstrate what these concentrations actually produce at the tissue level, see the TRIUMPH-1 results post and our overview of the glucagon component of retatrutide.

Related reading

• Retatrutide vs semaglutide
• Tirzepatide dosing schedule
• Semaglutide dosing schedule